HI-Bio
ClosedPrecision therapies for immune-mediated disease.
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- hi-bio.com
- Total Funding
- $215.0M
- Last Round
- $95.0M Series BJan 2024
- Rounds
- 2
About
HI-Bio is a clinical-stage biotechnology company developing precision therapies for severe immune-mediated diseases. The company's pipeline targets conditions with high unmet need including IgA nephropathy, atopic dermatitis, and alopecia areata, using a mechanism-based approach to selectively disrupt disease-driving immune pathways. Founded in 2020 and headquartered in South San Francisco, HI-Bio raised $70M in Series B financing in October 2023 before being acquired by Gilead Sciences in 2024 for approximately $1.15 billion.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...